CD24 and myeloid sarcoma: The results suggested that the CD24 Val/Val genotypes were associated with an increased risk of MS in all study subjects and Caucasians (OR = 2.28, 95% CI: 1.68–3.10, Pz < 0.001 and OR = 2.30, 95% CI: 1.66–3.20, Pz < 0.001, respectively).